Comprehensive analysis of 311 patients with locally advanced rectal cancer revealed a 26.4% pathological complete response rate and significant downstaging in 75.2% of cases. At a median follow-up of 36 months, local and distant recurrence rates were 5.7% and 12.5%, respectively. The five-year cancer-specific survival and disease-free survival rates reached 88.8% and 80.5%, with downstaged patients showing remarkably better outcomes. Total neoadjuvant therapy followed by total mesorectal excision demonstrates robust efficacy.
Journal Article by Ng JC, Sassun R (…) Larson DW et 7 al. in Eur J Surg Oncol
Copyright © 2025 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.